Amanta Healthcare Limited saw an off-market inter-se transfer of 1,50,400 equity shares within its promoter group on September 28, 2026. The transaction was executed at a consideration price of ₹190 per share, resulting in a total value of approximately ₹2.86 crore.

Pravinchandra Dhanjibhai Mehta disposed of the shares to Kirit Ambalal Desai. This movement adjusts individual holdings without altering the aggregate promoter stake. The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, alongside previous filings under the Insider Trading regulations.

Transaction specifics

Pravinchandra Dhanjibhai Mehta’s holding reduced from 19,82,763 shares (5.11%) to 18,32,363 shares (4.72%). Conversely, Kirit Ambalal Desai’s stake increased from 11,27,079 shares (2.90%) to 12,77,479 shares (3.29%). Both individuals are based in Texas, USA.

Regulatory compliance

The disclosures were submitted to BSE and NSE on September 30, 2026. The company confirmed receipt of declarations under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, on September 29, 2026. Nikhita Dinodia, Company Secretary & Compliance Officer, signed the filings.

The total equity share capital remained unchanged at 3,88,29,351 equity shares of ₹10 each before and after the transaction. No trades in derivatives were reported by these individuals during the period.

Amanta Healthcare Limited shareholders approved all five agenda items at its 31st Annual General Meeting held on September 16, 2026. The resolutions included the adoption of FY26 financial statements, director reappointment, and a revision in managing director remuneration.

The virtual meeting commenced at 12:09 pm and concluded at 12:48 pm. Chairman Bhavesh Girishbhai Patel confirmed the requisite quorum. A total of 34 members participated in the session, with voting conducted via CDSL’s remote e-voting platform from September 13 to September 15, 2026, and during the meeting.

Voting Results

Scrutinizer Kashyap R. Mehta & Partners reported that all resolutions passed with overwhelming support. The promoter group, holding 24,773,860 shares, voted in favour of all ordinary resolutions. For the special resolution regarding MD remuneration, promoters abstained from voting, while public shareholders approved it unanimously.

Governance and Compliance

Nimesh P Patel (DIN: 09044772) was reappointed as a director liable to retire by rotation. He is a Non-Executive and Non-Independent Director who has served on the Board since December 14, 2020. He holds a Bachelor of Science in Economics from Wharton School, University of Pennsylvania, and has over five years of experience in the pharmaceutical industry. Disclosures indicate he is a cousin of Chairman Bhavesh Girishbhai Patel.

The company appointed M/s. Kashyap R. Mehta & Partners as Secretarial Auditors for a term of five consecutive years, commencing from FY26-27 till FY30-31. The remuneration of the cost auditor for the financial year 2026-27 was ratified by the members.

Statutory Auditors Price Waterhouse Chartered Accountants LLP and Secretarial Auditors Kashyap R. Mehta & Partners attended the meeting. The Company Secretary reported no qualifications, observations, or adverse remarks in either the Statutory Auditor’s Report or the Secretarial Auditor’s Report.

Participation Details

Remote e-voting was available from September 13, 2026, to September 15, 2026. During the AGM, members present via video conferencing who had not cast remote votes were provided an additional opportunity to vote electronically. Nikhita Dinodia, Company Secretary and Compliance Officer, was authorized to declare the voting results. The scrutinizer unblocked results in the presence of two independent witnesses, Bandish Rana and Qaisar Abbas Bukhari.